Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity

Cancer surgery while necessary for primary tumor removal, has been shown to induce immune suppression and promote metastases in preclinical models and human cancer surgery patients. Activating the immune system and reversing immunosuppression have emerged as promising ways to treat cancer and they c...

Full description

Bibliographic Details
Main Authors: Lee-Hwa Tai, Almohanad A. Alkayyal, Amanda L. Leslie, Shalini Sahi, Sean Bennett, Christiano Tanese de Souza, Katherine Baxter, Leonard Angka, Rebecca Xu, Michael A. Kennedy, Rebecca C. Auer
Format: Article
Language:English
Published: Taylor & Francis Group 2018-06-01
Series:OncoImmunology
Subjects:
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1431082
id doaj-454ee486bf004eab94b8824731a7cd5e
record_format Article
spelling doaj-454ee486bf004eab94b8824731a7cd5e2020-11-25T03:02:11ZengTaylor & Francis GroupOncoImmunology2162-402X2018-06-017610.1080/2162402X.2018.14310821431082Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicityLee-Hwa Tai0Almohanad A. Alkayyal1Amanda L. Leslie2Shalini Sahi3Sean Bennett4Christiano Tanese de Souza5Katherine Baxter6Leonard Angka7Rebecca Xu8Michael A. Kennedy9Rebecca C. Auer10Ottawa Hospital Research InstituteOttawa Hospital Research InstituteOttawa Hospital Research InstituteOttawa Hospital Research InstituteOttawa Hospital Research InstituteOttawa Hospital Research InstituteOttawa Hospital Research InstituteOttawa Hospital Research InstituteOttawa Hospital Research InstituteOttawa Hospital Research InstituteOttawa Hospital Research InstituteCancer surgery while necessary for primary tumor removal, has been shown to induce immune suppression and promote metastases in preclinical models and human cancer surgery patients. Activating the immune system and reversing immunosuppression have emerged as promising ways to treat cancer and they can be safely employed in the perioperative period. In this study, we evaluated the immunotherapeutic potential of phosphodiesterase-5 (PDE-5) inhibitors to target surgery-induced myeloid-derived suppressor cells (MDSC) and restore natural killer (NK) cell function in the clinically relevant perioperative period. Immunocompetent murine tumor models of major surgery were used to characterize the functional suppression of surgery-induced MDSC and to assess the in vivo efficacy of perioperative PDE5 inhibition. In cancer surgery patients with abdominal malignancies, we assessed postoperative NK cell function following co-culture with MDSC and PDE5 inhibition. Perioperative PDE5 inhibition reverses surgery-induced immunosuppression. In particular, sildenafil reduces surgery-derived granulocytic-MDSC (gMDSC) function through downregulation of arginase 1 (ARG1), IL4Ra and reactive oxygen species (ROS) expression, enabling NK cell antitumor cytotoxicity and reducing postoperative disease recurrence. By removing surgery-derived immunosuppressive mechanisms of MDSCs, sildenafil can be combined with the administration of perioperative influenza vaccination which targets NK cells to reduce postoperative metastasis. Importantly, sildenafil reverses MDSC suppression in cancer surgery patients. These findings demonstrate that PDE5 inhibitors reduce postoperative metastasis by their ability to inhibit surgery-induced MDSC. Further clinical studies are warranted to investigate the immunotherapeutic role of PDE5 inhibitors in combination with cancer surgery.http://dx.doi.org/10.1080/2162402X.2018.1431082myeloid derived suppressor cellsmetastasesnk cell cytotoxicitypostoperative immunosuppressionsildenafil
collection DOAJ
language English
format Article
sources DOAJ
author Lee-Hwa Tai
Almohanad A. Alkayyal
Amanda L. Leslie
Shalini Sahi
Sean Bennett
Christiano Tanese de Souza
Katherine Baxter
Leonard Angka
Rebecca Xu
Michael A. Kennedy
Rebecca C. Auer
spellingShingle Lee-Hwa Tai
Almohanad A. Alkayyal
Amanda L. Leslie
Shalini Sahi
Sean Bennett
Christiano Tanese de Souza
Katherine Baxter
Leonard Angka
Rebecca Xu
Michael A. Kennedy
Rebecca C. Auer
Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity
OncoImmunology
myeloid derived suppressor cells
metastases
nk cell cytotoxicity
postoperative immunosuppression
sildenafil
author_facet Lee-Hwa Tai
Almohanad A. Alkayyal
Amanda L. Leslie
Shalini Sahi
Sean Bennett
Christiano Tanese de Souza
Katherine Baxter
Leonard Angka
Rebecca Xu
Michael A. Kennedy
Rebecca C. Auer
author_sort Lee-Hwa Tai
title Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity
title_short Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity
title_full Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity
title_fullStr Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity
title_full_unstemmed Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity
title_sort phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of natural killer cell cytotoxicity
publisher Taylor & Francis Group
series OncoImmunology
issn 2162-402X
publishDate 2018-06-01
description Cancer surgery while necessary for primary tumor removal, has been shown to induce immune suppression and promote metastases in preclinical models and human cancer surgery patients. Activating the immune system and reversing immunosuppression have emerged as promising ways to treat cancer and they can be safely employed in the perioperative period. In this study, we evaluated the immunotherapeutic potential of phosphodiesterase-5 (PDE-5) inhibitors to target surgery-induced myeloid-derived suppressor cells (MDSC) and restore natural killer (NK) cell function in the clinically relevant perioperative period. Immunocompetent murine tumor models of major surgery were used to characterize the functional suppression of surgery-induced MDSC and to assess the in vivo efficacy of perioperative PDE5 inhibition. In cancer surgery patients with abdominal malignancies, we assessed postoperative NK cell function following co-culture with MDSC and PDE5 inhibition. Perioperative PDE5 inhibition reverses surgery-induced immunosuppression. In particular, sildenafil reduces surgery-derived granulocytic-MDSC (gMDSC) function through downregulation of arginase 1 (ARG1), IL4Ra and reactive oxygen species (ROS) expression, enabling NK cell antitumor cytotoxicity and reducing postoperative disease recurrence. By removing surgery-derived immunosuppressive mechanisms of MDSCs, sildenafil can be combined with the administration of perioperative influenza vaccination which targets NK cells to reduce postoperative metastasis. Importantly, sildenafil reverses MDSC suppression in cancer surgery patients. These findings demonstrate that PDE5 inhibitors reduce postoperative metastasis by their ability to inhibit surgery-induced MDSC. Further clinical studies are warranted to investigate the immunotherapeutic role of PDE5 inhibitors in combination with cancer surgery.
topic myeloid derived suppressor cells
metastases
nk cell cytotoxicity
postoperative immunosuppression
sildenafil
url http://dx.doi.org/10.1080/2162402X.2018.1431082
work_keys_str_mv AT leehwatai phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
AT almohanadaalkayyal phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
AT amandalleslie phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
AT shalinisahi phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
AT seanbennett phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
AT christianotanesedesouza phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
AT katherinebaxter phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
AT leonardangka phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
AT rebeccaxu phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
AT michaelakennedy phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
AT rebeccacauer phosphodiesterase5inhibitionreducespostoperativemetastaticdiseasebytargetingsurgeryinducedmyeloidderivedsuppressorcelldependentinhibitionofnaturalkillercellcytotoxicity
_version_ 1724690959443165184